|
LSM1
|
LSM1 homolog, mRNA degradation associated |
- mRNA decay by 5' to 3' exoribonuclease
- mRNA decay by 5' to 3' exoribonuclease
|
|
|
|
LYN
|
LYN proto-oncogene, Src family tyrosine kinase |
- GPVI-mediated activation cascade
- Signaling by SCF-KIT
- Signaling by SCF-KIT
- Regulation of KIT signaling
- Cell surface interactions at the vascular wall
- FCGR activation
- PECAM1 interactions
- Fc epsilon receptor (FCERI) signaling
- Fc epsilon receptor (FCERI) signaling
- EPH-Ephrin signaling
- Role of LAT2/NTAL/LAB on calcium mobilization
- Role of LAT2/NTAL/LAB on calcium mobilization
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- FCERI mediated NF-kB activation
- Co-stimulation by CD28
- Co-inhibition by CTLA4
- EPHB-mediated forward signaling
- EPHB-mediated forward signaling
- EPHA-mediated growth cone collapse
- EPHA-mediated growth cone collapse
- EPH-ephrin mediated repulsion of cells
- Dectin-2 family
- CD209 (DC-SIGN) signaling
- CD22 mediated BCR regulation
- Cyclin D associated events in G1
- Platelet Adhesion to exposed collagen
- Signaling by Erythropoietin
- Signaling by Erythropoietin
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phospholipase C gamma (PLCG)
- Erythropoietin activates STAT5
- Erythropoietin activates RAS
- Erythropoietin activates RAS
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- FCGR3A-mediated IL10 synthesis
- FCGR3A-mediated phagocytosis
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Signaling by CSF1 (M-CSF) in myeloid cells
- Inactivation of CSF3 (G-CSF) signaling
- Inactivation of CSF3 (G-CSF) signaling
- Growth hormone receptor signaling
- Growth hormone receptor signaling
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
- Dasatinib
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- Bosutinib
- Ponatinib
- Nintedanib
- Fostamatinib
|
|
|
MAPK1
|
mitogen-activated protein kinase 1 |
- phospho-PLA2 pathway
- RAF-independent MAPK1/3 activation
- MAPK1 (ERK2) activation
- Signaling by NODAL
- Spry regulation of FGF signaling
- Signaling by Activin
- Golgi Cisternae Pericentriolar Stack Reorganization
- Frs2-mediated activation
- ERK/MAPK targets
- ERK/MAPK targets
- ERKs are inactivated
- Regulation of actin dynamics for phagocytic cup formation
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Oxidative Stress Induced Senescence
- Senescence-Associated Secretory Phenotype (SASP)
- Oncogene Induced Senescence
- Oncogene Induced Senescence
- FCERI mediated MAPK activation
- Regulation of HSF1-mediated heat shock response
- NCAM signaling for neurite out-growth
- Recycling pathway of L1
- RSK activation
- Signal transduction by L1
- Activation of the AP-1 family of transcription factors
- Thrombin signalling through proteinase activated receptors (PARs)
- Negative regulation of FGFR1 signaling
- Negative regulation of FGFR2 signaling
- Negative regulation of FGFR3 signaling
- Negative regulation of FGFR4 signaling
- RHO GTPases Activate WASPs and WAVEs
- RHO GTPases Activate NADPH Oxidases
- RAF/MAP kinase cascade
- MAP2K and MAPK activation
- Negative feedback regulation of MAPK pathway
- Negative regulation of MAPK pathway
- Neutrophil degranulation
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Signal attenuation
- Interferon gamma signaling
- Advanced glycosylation endproduct receptor signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- ESR-mediated signaling
- RUNX2 regulates osteoblast differentiation
- Regulation of PTEN gene transcription
- Regulation of the apoptosome activity
- Estrogen-stimulated signaling through PRKCZ
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
- Suppression of apoptosis
- Signaling downstream of RAS mutants
- Signaling by MAP2K mutants
- Signaling by MAPK mutants
- Signaling by RAF1 mutants
- FCGR3A-mediated phagocytosis
- Nuclear events stimulated by ALK signaling in cancer
- IFNG signaling activates MAPKs
- Negative Regulation of CDH1 Gene Transcription
- NPAS4 regulates expression of target genes
- NPAS4 regulates expression of target genes
- Growth hormone receptor signaling
- Signaling by LTK in cancer
- Transcriptional and post-translational regulation of MITF-M expression and activity
|
- Acetylsalicylic acid
- Minocycline
- Arsenic trioxide
- Olomoucine
- Phosphonothreonine
- Colforsin
- Purvalanol
- SB220025
- Seliciclib
- Perifosine
- N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
- N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE
- (S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
- (3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE
- 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE
- Hypothemycin
- [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
- 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine
- Turpentine
- Ulixertinib
|
|
|
MBL2
|
mannose binding lectin 2 |
- Lectin pathway of complement activation
- Initial triggering of complement
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
|
- O3-Sulfonylgalactose
- Methyl alpha-D-mannoside
- 4-(Hydrogen sulfate)-beta-D-galactopyranose
- Methyl beta-L-fucopyranoside
- N-acetyl-alpha-neuraminic acid
- alpha-L-methyl-fucose
- Alpha-Methyl-N-Acetyl-D-Glucosamine
|
- Tuberculosis
- Mannose-binding lectin pathway component defects, including the following two diseases: Mannose-binding lectin deficiency; Mannose-binding lectin-associated serine protease (MASP) 2 deficiency
|
|
PAEP
|
progestagen associated endometrial protein |
|
- 12-Bromododecanoic Acid
- Palmitic Acid
- Glycerin
|
|
|
PPFIA1
|
PPFI scaffold protein A1 |
- Serotonin Neurotransmitter Release Cycle
- Norepinephrine Neurotransmitter Release Cycle
- Glutamate Neurotransmitter Release Cycle
- Dopamine Neurotransmitter Release Cycle
- Acetylcholine Neurotransmitter Release Cycle
- Receptor-type tyrosine-protein phosphatases
|
|
|
|
PPFIBP2
|
PPFIB scaffold protein 2 |
- Receptor-type tyrosine-protein phosphatases
|
|
|
|
PRKCSH
|
PRKCSH beta subunit of glucosidase II |
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- N-glycan trimming in the ER and Calnexin/Calreticulin cycle
- Advanced glycosylation endproduct receptor signaling
- Post-translational protein phosphorylation
- Calnexin/calreticulin cycle
- Maturation of spike protein
- Maturation of spike protein
- Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
|
|
|
|
PTPN6
|
protein tyrosine phosphatase non-receptor type 6 |
- GPVI-mediated activation cascade
- Regulation of KIT signaling
- Signaling by ALK
- PECAM1 interactions
- Co-inhibition by PD-1
- Signal regulatory protein family interactions
- Platelet sensitization by LDL
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- CD22 mediated BCR regulation
- Neutrophil degranulation
- Interferon gamma signaling
- Regulation of IFNG signaling
- Interleukin-37 signaling
- Interferon alpha/beta signaling
- Interleukin receptor SHC signaling
- Regulation of IFNA/IFNB signaling
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Nuclear events stimulated by ALK signaling in cancer
- Growth hormone receptor signaling
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Co-inhibition by BTLA
|
|
|
|
PTPRCAP
|
protein tyrosine phosphatase receptor type C associated protein |
|
|
|
|
RASA1
|
RAS p21 protein activator 1 |
- Downstream signal transduction
- EPHB-mediated forward signaling
- EPHB-mediated forward signaling
- VEGFR2 mediated cell proliferation
- Regulation of RAS by GAPs
- PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
|
|
- RASA1-related disorders, including: Parkes-Weber slndrome; Capillary malformation-arteriovenous malformation (CM-AVM); Arteriovenous fistula (AVF)
|
|
RNF11
|
ring finger protein 11 |
|
|
|
|
SEMA4D
|
semaphorin 4D |
- Sema4D mediated inhibition of cell attachment and migration
- Sema4D induced cell migration and growth-cone collapse
- Other semaphorin interactions
|
|
|
|
SKAP1
|
src kinase associated phosphoprotein 1 |
|
|
|
|
SRC
|
SRC proto-oncogene, non-receptor tyrosine kinase |
- Signaling by ERBB2
- Nuclear signaling by ERBB4
- Downregulation of ERBB4 signaling
- PIP3 activates AKT signaling
- GAB1 signalosome
- Downstream signal transduction
- Constitutive Signaling by Aberrant PI3K in Cancer
- Integrin signaling
- GRB2:SOS provides linkage to MAPK signaling for Integrins
- p130Cas linkage to MAPK signaling for integrins
- G alpha (s) signalling events
- G alpha (i) signalling events
- G alpha (i) signalling events
- DCC mediated attractive signaling
- DCC mediated attractive signaling
- Netrin mediated repulsion signals
- Regulation of commissural axon pathfinding by SLIT and ROBO
- RAF activation
- MAP2K and MAPK activation
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates PTK2 signaling
- InlA-mediated entry of Listeria monocytogenes into host cells
- Regulation of RUNX1 Expression and Activity
- RUNX2 regulates osteoblast differentiation
- Regulation of RUNX3 expression and activity
- Extra-nuclear estrogen signaling
- RHOU GTPase cycle
- Activated NTRK2 signals through FYN
- Activated NTRK3 signals through PI3K
- Activated NTRK3 signals through PI3K
- Long-term potentiation
- GPER1 signaling
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- Signaling by CSF1 (M-CSF) in myeloid cells
- Degradation of CDH1
|
- Dasatinib
- RU84687
- RU79256
- N6-Benzyl Adenosine-5'-Diphosphate
- RU85493
- RU78262
- Phosphonotyrosine
- Malonic acid
- RU83876
- RU90395
- RU79072
- RU78783
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- PASBN
- 2-[4-[(Z)-2-Acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid
- PAS219
- DPI59
- RU82197
- Phenylphosphate
- RU78300
- RU79073
- RU82209
- ISO24
- RU85053
- RU78299
- Oxalic Acid
- RU78191
- Citric acid
- Paratoulene phosphate
- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
- Purvalanol A
- XL228
- Tirbanibulin
- Bosutinib
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- PD-168393
- [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
- PP-121
- 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
- N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
- (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
- Ponatinib
- Nintedanib
- Fostamatinib
|
|
|
TYK2
|
tyrosine kinase 2 |
- Interleukin-6 signaling
- Interleukin-6 signaling
- MAPK3 (ERK1) activation
- MAPK1 (ERK2) activation
- Other interleukin signaling
- Interleukin-10 signaling
- Interleukin-4 and Interleukin-13 signaling
- IL-6-type cytokine receptor ligand interactions
- Interleukin-20 family signaling
- Interleukin-35 Signalling
- Interleukin-12 signaling
- Interleukin-12 signaling
- Interleukin-23 signaling
- Interleukin-23 signaling
- Interleukin-27 signaling
- Interleukin-27 signaling
- Interferon alpha/beta signaling
- Regulation of IFNA/IFNB signaling
- Regulation of IFNA/IFNB signaling
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Potential therapeutics for SARS
- Inactivation of CSF3 (G-CSF) signaling
- Inactivation of CSF3 (G-CSF) signaling
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Signaling by ALK fusions and activated point mutants
- Evasion by RSV of host interferon responses
|
- 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
- Ruxolitinib
- Tofacitinib
- Baricitinib
- Fostamatinib
- Abrocitinib
- Deucravacitinib
|
- Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
|
|
UHRF2
|
ubiquitin like with PHD and ring finger domains 2 |
- SUMOylation of transcription cofactors
|
|
|
|
ZAP70
|
zeta chain of T cell receptor associated protein kinase 70 |
- Translocation of ZAP-70 to Immunological synapse
- Generation of second messenger molecules
- RHOH GTPase cycle
- Nuclear events stimulated by ALK signaling in cancer
|
- Staurosporine
- Fostamatinib
|
- Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
|